ASH 2020 | IMGN632: a novel CD123-targeted antibody-drug conjugate for R/R BPDCN
Daniel DeAngelo, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses the findings of a trial (NCT03386513) of IMGN632, a novel antibody-drug conjugate (ADC), in relapsed/refractory (R/R) blastic plasmacytoid dendritic cell neoplasm (BPDCN), a setting with poor outcomes and minimal treatment options. IMGN632 targets CD123, which is universally upregulated in BPDCN, and contains a DNA-alkylating indolinobenzodiazepine dimer (IGN). Trial results showed an encouraging overall response rate of 30% and a favorable tolerability profile. Given the limited efficacy and tolerability concerns of current therapy options for these pretreated patients, the responses to IMGN632 were promising, particularly in a cohort with high rates of prior anti-CD123 treatment exposure. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
